What Happened?
Cambridge, MA-based TCR2 Appointed Peter Olagunju as Chief Technology Officer
About the Company
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
About the Person
Peter Olagunju is Chief Technology Officer at TCR2. Previously, Peter held various senior IT leadership roles in the industry.
Info Source
News
Short Profile